21 May 2009
Prediction of graft loss and death in patients with primary sclerosing cholangitis (PSC)
O Kornasiewicz, K Dudek, Z Lewandowski, R Stankiewicz, M KrawczykAnn Transplant 2009; 14(1): 44-44 :: ID: 880358
Abstract
Background: The prognosis of patients with PSC can be accurately determined using Mayo Clinic Score (MRS). This is a mathematical model which predicts patient's survival and helps to determine individual patient's prognosis. The purpose of the study was to determine the risk of graft loss and/or death of patients who were listed or transplanted for PSC.
Material/Methods: We analyzed data of 52 patients, who were placed on the
transplant list due to PSC between January 2000 and November 2008 and either had or hadn't liver transplantation. The primary end point (EP1) of the study was the death of patients of any cause. The secondary composed end point (EP2) was: recurrence of the PSC or appearance of CCC or death related to primary liver disease after OLTx. The time of observation was 60 months. According to obtained MRS the patients were divided into 3 equal groups: group A (MRS<0.56), group B (0.56≤MRS<1.56) and group C (MRS>1.56). Each patient had calculated MRS using Mayo formula. Analysis was performed using the LIFETEST and PHREG Procedure of SAS System.
Results: Risk of EP1 occurence was 2.0 per 1 point of MRS (p<0.0006). Risk of EP2 was 2.1 per 1 point of MRS (p< 0.001). In groups B and C compared with group A the risk of death were: 0.79(NS) and 6.59(p<0.08), respectively. Percentages of 5 years patients survival rate were 94%, 94% and 45% according to groups A, B and C, respectively.
Conclusions: The risk of death in patients with Mayo Risk Score above 1.56 is 6.59 fold higher compared to those with MRS below 0.56 (Group A). MRS greater than 1.56 significantly decreases 5 years survival of patients with primary sclerosing cholangitis.
Keywords: Liver Transplantation, clinical outcome
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






